Are you Dr. Barlin?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 68 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
319 S Manning Blvd
Ste 301
Albany, NY 12208Phone+1 518-458-1390Fax+1 518-459-3271
Summary
- Dr. Joyce Barlin, MD is an obstetrician/gynecologist in Albany, New York. She is currently licensed to practice medicine in New York. She is affiliated with St. Peter's Hospital, Albany Medical Center, and Vassar Brothers Medical Center.
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Gynecologic Oncology, 2011 - 2014
Johns Hopkins UniversityResidency, Obstetrics and Gynecology, 2006 - 2010
Albany Medical CollegeClass of 2006
Certifications & Licensure
NY State Medical License 2010 - 2027- American Board of Obstetrics and Gynecology Obstetrics & Gynecology
- American Board of Obstetrics and Gynecology Gynecologic Oncology
Publications & Presentations
PubMed
- ENGOT-EN20/GOG-3083/XPORT-EC-042 - A phase III, randomized, placebo-controlled, double-blind, multicenter trial of selinexor in maintenance therapy after systemic ther...Ignace Vergote, Alejandro Perez Fidalgo, Giorgio Valabrega, Bradley J Monk, Thomas Herzog
International Journal of Gynecological Cancer. 2024-08-05 - Homologous recombination deficiency should be tested for in patients with advanced stage high-grade serous ovarian cancer aged 70 years and over.Omali Pitiyarachchi, Peter J Ansell, Robert L Coleman, Minh H Dinh, Laura Holman
Gynecologic Oncology. 2024-08-01 - Maintenance with mirvetuximab soravtansine plus bevacizumab vs bevacizumab in FRα-high platinum-sensitive ovarian cancer.David M O'Malley, Tashanna Myers, Pauline Wimberger, Toon Van Gorp, Andres Redondo
Future Oncology. 2024-01-01
Press Mentions
UPDATE - OncoC4 Announces First Patient Dosed in PRESERVE-004, a Phase 2 Clinical Trial of ONC-392 in Combination with KEYTRUDA® (Pembrolizumab) in Patients with Platinum-Resistant Ovarian CancerDecember 30th, 2022
